

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A human Human anti-idiotypic antibody Fab- or scFv- fragment, characterized by the ability to mimic- which is capable of mimicking Her-2/neu tumor associated antigen, and which comprises CDR1H of sequence SYAMS (SEQ ID No: 15), CDR1L of sequence QGDSLSRSYYAS (SEQ ID No: 16), CDR2H of sequence SGGTTYADSVKG (SEQ ID No: 17), CDR2L of sequence GKNNRPS (SEQ ID No: 18), and (i) CDR3H of sequence SEQ ID No: 3 and CDR3L of sequence SEQ ID No: 4, or (ii) CDR3H of sequence SEQ ID No: 5 and CDR3L of sequence SEQ ID No: 6.

2. (Original) The fragment of claim 1, that comprises a sequence SEQ ID No: 3 in the CDR3 region of the VH domain and a sequence SEQ ID No: 4 in the CDR3 region of the VL domain.

3. (Original) The fragment of claim 1, that comprises a sequence SEQ ID No: 5 in the CDR3 region of the VH domain and a sequence SEQ ID No: 6 in the CDR3 region of the VL domain.

4. (Previously presented) The fragment of claim 1, which is directed against trastuzumab F(ab')₂.

5. (Currently Amended) The fragment of claim 2, which comprises the amino_acid sequence SEQ ID No: 1, this fragment being designated scFv 40.

6. (Currently Amended) The fragment of claim 3, which comprises the amino_acid sequence SEQ ID No: 2, this fragment being designated scFv 69.

7. (Previously Presented) A multimer of the antibody fragment defined in claim 1.

8. (Previously Presented) A pharmaceutical composition comprising an antibody fragment according to claim 1, or a multimer of the antibody fragment, in association with a pharmaceutically acceptable carrier.

9-15. (Cancelled).